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A B S T R A C T
Introduction: IRI results from the interruption then reinstatement of an organ's blood supply, and this poses a
significant problem in liver transplantation and resectional surgery.
In this paper, we explore the role T cells play in the pathogenesis of this injury.
Materials & methods: We used an in vivo murine model of warm partial hepatic IRI, genetically-modified mice, in
vivo antibody depletion, adoptive cell transfer and flow cytometry to determine which lymphocyte subsets
contribute to pathology. Injury was assessed by measuring serum alanine aminotransfersase (ALT) and by his-
tological examination of liver tissue sections.
Results: The absence of T cells (CD3εKO) is associated with significant protection from injury (p= 0.010).
Through a strategy of antibody depletion it appears that NKT cells (p= 0.0025), rather than conventional T
(CD4+ or CD8+) (p= 0.11) cells that are the key mediators of injury.
Discussion: Our results indicate that tissue-resident NKT cells, but not other lymphocyte populations are re-
sponsible for the injury in hepatic IRI. Targeting the activation of NKT cells and/or their effector apparatus
would be a novel approach in protecting the liver during transplantation and resection surgery; this may allow us
to expand our current criteria for surgery.
1. Introduction
Liver failure is increasing dramatically in the UK population [1].
Currently, liver transplantation is the only effective treatment for pa-
tients with end-stage disease, giving an average of 17–22 years of ad-
ditional life [1–3]. Ischemia-reperfusion injury (IRI) limits access to
liver transplantation and is linked to early graft failure [4–6]. Marginal
organs including those from older or steatotic donors are particularly
susceptible to IRI [7]. The problem of marginal organs is becoming
more prevalent and results from changes in donor profile and a rise of
donation after cardiac death (DCD) [8]. IRI also poses a significant
challenge in the contexts of major liver resection surgery [9] and hy-
poxic hepatitis often seen in critically ill patients [10].
IRI results from the interruption then reinstatement of an organ's
blood supply. The initial ischemic injury leads to disruption of cellular
integrity with the release of Danger Associated Molecular Patterns
(DAMPs). DAMPs initiate a secondary (immune-mediated) response
within the liver. This immune response causes further collateral da-
mage to cells that may have otherwise survived the primary ischemic
injury [11,12]. Mice deficient in both B and T cells are protected from
hepatic IRI [13–15]. We have previously demonstrated that it is T cells,
not B cells (or IgM), that are the key mediators of injury [15]. This fits
with work from other laboratories, identifying a variety of “key” T cells
populations [16–18]. It should be noted that Caldwell et al. found
CD4+ lymphocytes to be protective in their model of IRI [19]; at least
in our hands, we could not attribute this protection to CD4+Foxp3+
regulatory T cells (TReg) [20].
There is a significant enrichment of non-conventional T cells within
the liver [21–23], with Natural Killer T (NKT) cells accounting for up to
30% of the resident intrahepatic lymphocytes. Hepatic NKT play an
important role in hepatic immunosurveillance [24] and are linked with
both immunosuppressive and pro-inflammatory responses [25]. They
are capable of rapidly (within 1–2 h) producing large amounts of pro-
inflammatory cytokines, including interferon-gamma (IFNγ), IL-4 and
TNFα [26,27].
In this paper, we explore the role T cell subsets play in the patho-
genesis of hepatic IRI.
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2. Materials and methods
2.1. Ethical approval & animal welfare
Following local ethical approval at the University of Edinburgh,
animal work was carried out according to UK Home Office regulations
(Animals Scientific Procedures Act 1986) under licenses 60/4045. Mice
were housed under specific pathogen-free conditions at the University
of Edinburgh. All wild type (WT), knockout and transgenic mice were
age-matched male mice on a C57BL/6J background. RAG1−/− mice
lack both mature B and T cells [28]. CD3εKO mice lack mature T cells
[29].> 95% of CD4+ T-cells in OT-II mice express αβ-T Cell Re-
ceptors (TCR) recognising chicken ovalbumin [30]. IL-17RA−/− mice
lack the IL-17 Receptor alpha chain and are unresponsive to both IL-17
(A-F) and IL-25 [31]. General anaesthesia (GA) was induced via inhaled
isoflurane and post-operatively subcutaneous opioid analgesia (bupre-
norphine) was administered. Animals were sacrificed under GA by
terminal exsanguination by way of cardiac puncture.
2.2. Surgical model of hepatic IRI
In this model of warm partial hepatic IRI, an atraumatic clamp was
applied to the vascular pedicle supplying the left lobe for 20–50 min;
the liver was then allowed to reperfuse for up to 24 h. Intraoperative
core body temperature was maintained at 36 °C with a homeothermic
blanket system (Harvard Apparatus, Edenbridge, UK) to minimise the
masking effects of hypothermia on liver IRI [32].
The extent of any liver injury was assessed in terms of the serum
level of alanine aminotransfersase (ALT), a biochemical marker of liver
injury [33]. ALT was measured on a Cobas Fara centrifugal analyser
(Roche Diagnostics Ltd., Welwyn Garden City, UK) using a commer-
cially available kit (Alpha Laboratories Ltd., Eastleigh, UK). ALT was
correlated with the histological evidence of injury seen on sections of
formalin fixed tissue stained with haematoxylin and eosin (H & E).
2.3. In vivo antibody depletion
2.3.1. CD4 and CD8 depletion
We have previously used monoclonal antibodies YTS169.4.2.1 and
YTS191.1.1.2 in vivo to deplete CD8+ and CD4+ cells respectively
[34]. Mice were given an intraperitoneal (i.p.) injection of 50μg CD8
depleting antibody (YTS 169.4.2.1) or 100μg of CD4 depleting antibody
(YTS 191.1.1.2) or isotype control (AFRC MAC 51) made up to 150 μl in
PBS at days -6 and days -2 prior to surgery; antibodies were sourced
commercially (Immunosolv, Edinburgh, UK). This regimen gave 99%
depletion of CD8+ T cells in the spleen and liver using YTS 169.4.2.1
and 91% of CD4+ T cells using YTS 191.1.1.2 (data not shown); this is
consistent with that established in the literature [34,35].
2.3.2. NK and NKT depletion
PK136 (BioXcell, West Lebanon, USA) was used to deplete NK1.1+
cells. On a C57BL/6 background this depletes both NK and NKT cells
[36,37]. Mice were given an i.p. injection of either 100μg PK136 or
mouse IgG2a isotype control (C1.18.4, BioXcell) 48 h pre-operatively.
This gave a depletion of 91% CD3intNK1.1+ cells (data not shown) in
line with that described in the literature [36–38].
NK cells were selectively depleted by anti-asialo GM1 antibody
[39]. Mice received i.p. injection of 30 μl reconstituted anti-asialo GM1
antibody (Wako, Neuss, Germany) or an equivalent volume of rabbit
serum (Sigma-Aldrich) at day -1 relative to surgery. Similar to reports in
the literature [38,40,41], this regimen gave a depletion of over 90% NK
cells (data not shown).
2.4. Flow cytometry
Single cell preparations from the liver were generated by a
combination of mechanical disruption (GentleMACS, Miltenyi Biotec,
Bisley, UK) and enzymatic digestion (2 mg/ml Collagenase D, Roche).
These were then passed through a 70 μm filter and centrifuged at 50g
for 5 min to remove debris and hepatocytes. Red cells were lysed (Red
Cell Lysis Buffer, Sigma-Aldrich, Poole, UK). Immune cells were isolated
by positive selection using a CD45+ MicroBead AutoMACS separation
(Miltenyi Biotec, Bisley, UK) and then stained with a fixable Live-Dead
marker (Life Technologies, Paisley, UK) and a multi-colour panel of
antibodies, including CD3, CD4, CD8, CD19 and NK1.1 (Biolegend, San
Diego, USA). NKT cells were also identified using PBS-57 tetramers, an
analogue of alpha-galactosylceramide developed by Dr. Paul Savage
(The NIH Tetramer Facility, Emory University, Atlanta, USA) and
complexed to CD1d tetramers [42].
Samples were then run on a BD LSR II Fortessa (BD Biosciences,
Oxford, UK) and analysed with FlowJo software (Tree Star, Ashland,
USA). T cells were defined as CD3+CD19− cells and NKT cells as
CD3intNK1.1+ (or CD3+Tetramer+) cells, within a forward-side
scatter defined lymphocyte gate (Supplemental Fig. 1).
2.5. Adoptive transfer
Isolation of lymphocytes from spleen was performed by mechanical
disaggregation through a 40 μm filter. Cells were transferred either as
mixed populations (e.g. “splenic lymphocytes”), or after purification
with AutoMACS CD4+ MicroBeads, using previously published cells
transfer protocols [43,44].
2.6. Immunohistochemistry
Tissue from the models of murine liver injury was fixed in metha-
carn (60% methanol, 30% chloroform, 10% glacial acetic acid (Sigma-
Aldrich)). Sections were deparaffinised and rehydrated before en-
dogenous peroxidase and avidin/biotin activity were quenched, prior to
incubating with a rat monoclonal anti-mouse Ly6g antibody (Ab25377,
Abcam, Cambridge, UK) at a dilution of 1 in 100. Slides were subse-
quently incubated at room temperature with polyclonal rabbit anti-rat
biotinylated secondary antibody (E0468, DAKO, Ely, UK) at 1 in 400
dilution for 40 min. Sections were then developed with VectaStain RTU
Elite (Vector Laboratories, Peterborough, UK) followed by diamino-
benzidine (DAB125, Spring Biosciences, Pleasanton, UK), before being
counterstained.
2.7. Statistical analysis
Groups were analysed with the aid of Prism 5 for Mac OSX
(Graphpad Software, La Jolla, USA); specific statistical methods are
referred to in the results section. All values in graphs represent
mean ± standard error of the mean (SEM) unless stated otherwise.
3. Results
3.1. T cells play a central role in the secondary immune-mediated injury
RAG1−/−mice are deficient in both mature B and T cells and were
significantly protected from experimental hepatic IRI across a range of
ischemic injuries (Fig. 1). There was significant protection in RAG1−/
− mice up to a point where the observed injury in RAG1−/− and WT
converged; this corresponded to complete ischemic necrosis within this
model. T cell deficient (CD3εKO) mice were also significantly protected
from injury (Fig. 1).
WT and RAG1−/− mice underwent 20–50 min of warm left lobe
hepatic ischemia and were reperfused for 24 h. There was significant
protection in RAG1−/− mice (which lack IgM, T and B cells) com-
pared to WT controls (Kruskal-Wallis p= 0.0058, n > 3 per time-
point). We had previously shown this was not as a result of B cells (or
IgM) [15]. Mice lacking T cells (CD3εKO) or WT controls underwent
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40 min ischemia and were then reperfused for 24 h (n= 12 per arm).
There was significant biochemical protection (Mann-Whitney
p= 0.010) in CD3εKO mice; this corresponded with histological pro-
tection (representative H & E stained sections ×25 magnification).
3.2. Tissue-resident rather than recruited T cells are responsible for injury
Following ischemic injury, there was a significant and rapid influx
of immune cells (defined as CD45+) into the post-ischemic lobe
(Fig. 2A); these were predominantly (Ly6g+) neutrophils (Fig. 2B).
With increasing time there was a decrease in the number of viable T
cells found within the post-ischemic liver and no significant mobilisa-
tion of T cells following reperfusion injury. Taken together with the
protection seen in CD3εKO mice (Fig. 1), this points to tissue-resident
(rather than recruited) T cells being key mediators of the secondary
immune-mediated injury.
To look at whether there was a change in the immune composition
following IRI, WT mice were exposed to 40 min left lobe ischemia and
reperfused for 3, 6 or 12 h (n= 4/group). T cells were defined as
CD3+CD19- gated lymphocytes. The immune cells isolated within the
ischemic lobe were initially analysed by flow cytometry. There was a
significant influx of immune cells (defined as CD45+ cells) into the
injured left lobe (Kruskall-Wallis p= 0.0080) (A). The number of vi-
able T cells was found to decrease significantly with time following
reperfusion (Kruskall-Wallis p= 0.0043); this was predominantly due
to cell death (as defined by positive staining for a live-dead marker)
(Kruskall-Wallis p= 0.0070) (A). Few neutrophils are found in unin-
jured areas of liver, but are a major component of the immune cell
influx following IRI (B). Here neutrophils are defined by
immunohistochemistry as cells positively staining for Ly6g (re-
presentative section shown).
3.3. Hepatic IRI is independent of IL-17
Interleukin-17 (IL-17) has been linked with the pathology of a
number of autoimmune diseases [45] and is important in neutrophil
chemotaxis [46]. Given the significant role of T cells (Fig. 1) and re-
cruitment of neutrophils to the site of liver injury (Fig. 2B), it was
proposed that Th17 cells, which are an important source of IL-17, may
play a significant role in the pathology of this injury. IL-17RA−/−
mice had no reduction in injury compared to WT controls (Fig. 3A); this
implied that neither IL-17 (A-F) nor IL-25 play a critical in the patho-
genesis of hepatic IRI. Neutrophils were recruited to the site of injury in
these mice, implying that IL-17 was not an essential chemoattractant of
neutrophils in this setting (Fig. 3B).
Given role for T cells and the influx of neutrophils (Figs. 1 and 2),
mice deficient in IL-17 Receptor subunit A (IL-17RA−/−) (n= 5/
group) were used to see whether there was a significant role for Th17
cells in the context of this injury. There was no significant protection
(Mann-Whitney p= 1) seen in IL-17RA−/− mice compared to WT
controls following 40 min ischemia and 24 h reperfusion (A). Further-
more, there was recruitment of neutrophils into sites of liver injury
following IRI in IL-17RA−/− mice (B) (representative section shown),
suggesting that neither IL-17 nor IL-25 are critical to the recruitment of
neutrophils in this model.
Fig. 1. T cells are key mediators of warm hepatic IRI.
Fig. 2. There is no significant influx of T cells into the liver during IRI.
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3.4. CD4+ TCR specificity has no significant bearing on injury
Others have previously implicated CD4+ T cell activation via an
antigen-dependent process as playing a significant role in injury [37].
OT-II mice have> 95% of the TCR on CD4+ T cells specific for
chicken ovalbumin [30]. It was therefore proposed that, if TCR re-
cognition of tissue expressed antigen was important in IRI, these mice
would be protected from injury. There was no protection observed in
OT-II mice compared to WT controls (see Fig. 4).
OT-II mice have> 90% of the TCR on CD4+ T cells specific for
chicken ovalbumin. OT-II mice and WT controls underwent 40 min
ischemia and 24 h reperfusion; there was no significant difference in
the observed injury (n= 5 per group, representative data from 2 ex-
periments). To assess the role of conventional (CD4+ and CD8+) T
cells, mice were injected with isotype control (n= 10) or CD4
(n= 10), CD8 (n= 9) or CD4 & CD8 (n= 4) depleting antibodies at
days -6 and -2 prior to surgery (40 min ischemia followed by 24 h re-
perfusion). Despite significant depletion of CD4+ and/or CD8+ T cells
(as detailed in methods), there was no significant reduction in the
biochemical evidence of injury compared to isotype control (Kruskal-
Wallis p= 0.10).
While this implied that conventional activation of CD4+ T cells is
not important, there may be a role for CD8+ T cells or non-classical
CD4+ T cells activation. To examine the roles of CD4+ or CD8+ T
cells in hepatic IRI, systemic antibody depletion of CD4+ and CD8+
cells was performed. Despite significant depletion of CD4+ (83%) and
CD8+ (99.9%) cells there was no significant reduction in injury. To
exclude there being sufficient redundancy in the system, both CD4+
and CD8+ cells were depleted synchronously (86%), and still there was
no reduction in the observed injury (p= 0.11) (Fig. 4).
Together with the protection in CD3εKO mice (Fig. 1), this implied
that neither conventional CD4+ nor CD8+ T cells are significantly
involved in the pathogenesis of the observed injury. This would also fit
with the observation that adoptive transfer of splenic CD4+ T cells,
which are mainly conventional, failed to reconstitute injury (Supple-
mental Fig. 1). Hepatic NKT cells have an intermediate expression of
TCRs compared to their conventional counterparts and can be either
CD4+, CD8+ or CD4/CD8 double negative [24].
3.5. Depletion of NKT cells reduces injury
We found that NKT cells are significantly enriched within the liver,
but account for only a minor population of T cells within the spleen
(Supplemental Fig. 2); this fits with data in the published literature
[21]. Mice were treated with anti-NK1.1 antibody, which depletes both
NK and NKT cells. There was a significant reduction in the observed
injury (p= 0.0025) (Fig. 5). Data from RAG1−/− and CD3εKO mice
(Fig. 1), both having an intact NK compartment, but lacking NKT cells,
suggested that NK cells do not play a significant role in experimental
IRI. To test this, NK cells were selectively depleted in WT mice with
anti-asialo GM-1 antibody; there was no observed protection, de-
spite> 90% depletion of NK cells (Fig. 5).
Mice were injected i.p. 48 h pre-operatively with 100μg PK136 or
mouse IgG2a isotype control (ISO); on a C57BL/6 background this
depletes both NK and NKT. The average depletion of CD3int+ cells by
PK136 was 91% compared to the isotype control. Mice were subjected
to a 40 min ischemic injury and reperfused for 24 h (n= 8). Mice
treated with PK136 were significantly protected from hepatic IRI
Fig. 3. Hepatic IRI and recruitment of neutrophils is in-
dependent of IL-17 and IL-25.
Fig. 4. Conventional T cells are not important in hepatic
IRI.
Fig. 5. NKT (but not NK) cells are key mediators of warm
hepatic IRI.
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(Mann-Whitney p= 0.0025). To exclude this being as a result of NK
cells, mice were injected at day-1 with 30 μl anti-asialo GM1 antibody
or rabbit serum to selectively deplete them. This led to a significant
depletion of 90–97% NK cells. However, following 40 min ischemia and
24 h reperfusion; there was no significant difference in the biochemical
evidence of injury (representative data from one experiment (n= 5 per
group), Mann-Whitney p= 0.84).
4. Discussion
While conflicting data exist within the literature about the protec-
tive or pathogenic nature of CD4+ cells [16,17,19], we looked directly
at the role T cells play in hepatic IRI. The absence of T cells (CD3εKO
mice) was associated with significant protection from injury (Fig. 1).
Work using TCR−/− mice has been performed in models of renal IRI,
where T cells were also found to be key mediators of injury [47,48]. We
have previously published that B cells [15] and regulatory T cells play
no significant role in this model or warm hepatic IRI [20]. Others have
reported T cells to be essential for cerebral [49,50], cardiac [51], pul-
monary [52], mesenteric [53] and renal IRI [47,48], indicating
common mechanisms in IRI irrespective of the organ involved.
The timeframe in which IRI occurs (minutes to hours) precludes a
“classical” (conventional) T cell response involving clonal expansion
and migration of effector populations to the site of injury (days). Work
presented here using mice with a restricted CD4+ TCR repertoire
(Fig. 4), combined with data from Khandoga et al., in which they found
no reduction in injury following in vivo antibody blockade of MHC II
[16], suggests that the observed pathogenic role of T cells in IRI cannot
result from classical epitope-specific peptide: MHC-TCR mediated ac-
tivation. This implicates innate rather than conventional T cells in the
pathogenesis of hepatic IRI. The lack of a role for conventional CD4+ T
cells in hepatic IRI together with the IL-17RA−/− data (Fig. 3), con-
firms that Th17 cells (along with IL-17 and IL-25) are not critical to this
injury or neutrophil recruitment to the site of injury. This fits with work
from others, who have shown that neutrophils are directly recruited by
danger signals (e.g. adenosine triphosphate) to focal areas of liver ne-
crosis [54].
NKT cells are significantly enriched within the liver [22,23]. In this
study, we found they accounted for 10–15% of all lymphocytes, com-
pared to< 1% in the spleen (Supplemental Fig. 2). Hepatic lympho-
cytes express characteristic chemokine receptors, which play a critical
role in the trafficking of T cells through the liver, maintaining tissue
resident populations of T cells and in liver inflammation [55–58]. Given
the differences in the baseline characteristics of hepatic and splenic T
cells, it is perhaps not surprising that the adoptive transfer experiments
using splenic-derived lymphocytes in an acute model of liver injury
failed to recapitulate injury (Supplemental Figs. 1 and 3), even before
their specificity, activation status and expression of trafficking re-
ceptors are considered.
Kuboki et al. also found a significant role for NKT cells in their in
vivo experiments utilising anti-CD1d blocking antibodies (to block NKT
activation) and PK136 depleting antibody (to deplete all NK1.1+ cells)
[37]. The reduction of injury, through the blockade of CD1d, points to
this being via conventional activation of NKT cells (as opposed to via
non-TCR receptors) [37]. The work we present here extends that of
Kuboki et al., by specifically showing that NK cells (which are also
NK1.1+ on a C57BL/6 background) do not play a significant role in
hepatic IRI (Fig. 5). Further evidence for this comes from the significant
protection observed in RAG1−/− mice (Fig. 1), which have functional
NK and innate lymphoid cell compartments. The timescale involved
also fits with NKT cells being the important population of T cells in IRI,
as they are capable of rapidly producing large amounts of pro-in-
flammatory cytokines [26,27]. The speed at which NKT cells produce
cytokines is thought to be related to pre-formed intracellular stores of
mRNA leaving them “poised for action” [59].
Most liver transplant surgeons will decline a liver for
transplantation if it is deemed at risk of significant IRI. This is because
of concerns about early allograft dysfunction, which is associated with a
worse short-term mortality as well as poorer 1, 3 and 5 year graft and
patient survival [60–63]. Liver-resident NKT cells have probably
evolved to recognise liver damage arising from the release of DAMPs
caused by fulminant hepatic infections. Understandably they cannot
distinguish that scenario from the 21st century concepts of organ
transplantation or liver resection surgery.
Machine organ perfusion (such as ex-vivo normothermic perfusion
(EVNP)) is an emerging technology, which restores circulation to a
retrieved organ prior to transplantation [64]. The implication of the
findings presented in this paper is that by simply putting a lymphocyte
filter into the machine perfusion circuit to “filter off” lymphocytes may
not be sufficient to provide substantial protection from IRI. This is be-
cause it is the tissue-resident (not circulating) NKT population that are
key to injury and will need to be targeted pharmacologically rather
than mechanically. This technique of capturing circulating donor leu-
cocytes during machine perfusion, may have longer term benefits in
terms of modulating the allogenic immunogenicity of the transplant
[65,66]. Beyond machine perfusion our work also suggests that im-
munotherapy solely targeting the recruitment of T cells into the liver is
unlikely to have a significant impact in combating IRI.
While further work to dissect out the exact nature of NKT cell ac-
tivation in hepatic IRI is also required, it does suggest that targeting the
activation of NKT cells and/or their effector apparatus either in vivo or
during ex-vivo perfusion, could be a better and novel approach to
minimising the (immune-mediated) secondary liver injury seen. Based
on the window of protection we see in immunodeficient mice (Fig. 1),
the use of cytoprotective strategies alone (such as up-regulating of
heme oxygenase-1 (HO-1) [67–69]) may only give limited protection
due to the effects of the secondary immune response. Furthermore we
showed no matter how potent an immunosuppressive treatment
strategy is, this can only be used effectively as a treatment when the
index ischemic event is “survivable”.
Immunomodulatory and cytoprotective therapeutic strategies are,
therefore, likely to be best used in combination and may in fact be
synergistic. Effective therapies against IRI may allow us to expand our
criteria for liver transplantation (as well as resection surgery) and de-
crease early organ dysfunction along with its long-term sequelae.
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